Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity ...
A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide ...
Zepbound (tirzepatide) is a brand-name injection prescribed for weight loss, weight management, and more. You may need to take Zepbound for several months to see the full effects of the drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback